Clinical trials: Celecoxib, completed
Neurofibromatosis 1
Medical Treatment of "High-Risk" Neurofibromas
Patients with neurofibromatosis type 1 (NF1) commonly develop non-cancerous tumors called plexiform neurofibromas. These tumors can be defined as "high-risk" when they result in severe pain, physical disability, organ dysfunction…
- Trial name
- NCT00846430
- Testing
- Peg-Interferon alpha-2b, Celecoxib (Celebrex), Temozolomide (temodar)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Corewell Health West
Major Depressive Disorder
Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder
The purpose of this study is to determine if translocator protein total distribution volume (TSPO VT) is elevated in major depressive disorder that is not responding to medication and if adding minocycline can affect TSPO VT.
- Trial name
- NCT02362529
- Testing
- Minocycline, Celecoxib
- Where
- Canada
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Osteoarthritis
Perioperative Pain Control With Celecoxib (Celebrex) in Total Knee Arthroplasty
We propose that administration perioperative celecoxib is effective to control postoperative VAS pain scores, improve rehabilitation results, and decrease narcotics usage in total knee replacement patients.
- Trial name
- NCT00598234
- Testing
- Celecoxib (Celebrex)
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Pelubiprofen, Celebrex
Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients
A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. \& Celebrex Cap. for Comparative Evaluation of Safety \& Efficacy in Rheumatoid Arthritis Patients
- Conditions
- Pelubiprofen, Celebrex, Rheumatoid Arthritis
- Trial name
- NCT01781702
- Testing
- Pelubiprofen 30 mg, Celebrex 200 mg
- Volunteers
- 120 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Pain
A Trial Assessing the Outcome of Celecoxib Administration Versus Placebo Following Anterior Cruciate Ligament (ACL) Reconstruction
The aim of this study is to directly compare the clinical outcomes of both the celecoxib and placebo groups following anterior cruciate ligament (ACL) reconstruction. The study will have short and long term goals.
- Trial name
- NCT01186887
- Testing
- Celecoxib
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Ottawa Hospital Research Institute
Head and Neck Cancer
Celecoxib in Treating Patients With Precancerous Lesions of the Mouth
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of celecoxib may be an effective way to prevent the further development of precancerous lesions in the mouth.
- Trial name
- NCT00014404
- Testing
- celecoxib
- Where
- 3 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteoarthritis, Knee
Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).
This study will investigate the efficacy and safety of lumiracoxib in patients with primary knee osteoarthritis (OA).
- Trial name
- NCT00366938
- Testing
- Lumiracoxib
- Where
- United States
- Volunteers
- 1,464 people
- Sponsor
- Novartis
Knee Osteoarthritis
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
This study will evaluate the efficacy and safety of using lumiracoxib in the treatment of patients with knee osteoarthritis (OA)
- Trial name
- NCT00367315
- Testing
- Lumiracoxib
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 1,684 people
- Sponsor
- Novartis
Pancreatic Cancer
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00068432
- Testing
- Celecoxib, Gemcitabine Hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00061906
- Testing
- celecoxib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Osteoarthritis, Rheumatoid Arthritis
The Standard Care Versus Celecoxib Outcome Trial
The Standard Care versus Celecoxib Outcome Trial (SCOT) is a large streamline safety study designed to compare the cardiovascular safety of celecoxib versus traditional non-selective Non Steroidal Anti-Inflammatory Drug (NSAID)…
- Trial name
- SCOTLSSS (NCT00447759)
- Testing
- Celecoxib, Diclofenac
- Where
- 10 sites in Denmark, Netherlands and 1 more
- Volunteers
- 7,297 people
- Sponsor
- University of Dundee
Osteoarthritis
Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)
This study will determine whether glucosamine, chondroitin sulfate and/or the combination of glucosamine and chondroitin sulfate are more effective than placebo and whether the combination is more effective than glucosamine or…
- Trial name
- NCT00032890
- Testing
- glucosamine, chondroitin sulfate, glucosamine and chondroitin sulfate combined
- Where
- 16 sites in United States
- Volunteers
- 1,588 people
- Sponsor
- US Department of Veterans Affairs
Mouth Neoplasms
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
The poor survival of Veterans with oral cancer underscores the significance of identifying new treatment approaches. The proposed studies will test a new 2 pronged immunotherapeutic approach for oral cancer patients which lessen…
- Trial name
- NCT00953849
- Testing
- Celecoxib, Calcitriol, Celecoxib plus Calcitriol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- VA Office of Research and Development
Brain and Central Nervous System Tumors
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00047281
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 3 sites in United States
- Sponsor
- Dana-Farber Cancer Institute